GALECTIN-3 LEVEL IN pATIENTS WITH mETAbOLIC SYNDROmE AND CORONARY HEART DISEASE
https://doi.org/10.15829/1560-4071-2017-3-30-36
Abstract
Aim. To assess the level of galectin-3 in blood serum of patients with metabolic syndrome (MS), including comorbidity with coronary heart disease (CHD), for evaluation of its significance as fibrosis marker in MS.
Material and methods. Totally, 43 MS patients studied with CHD signs, and 33 patients non-MS of comparable age, of those CHD was diagnosed in 17. Mean age in MS group was 62,7±10,3 y.o. at baseline, in controls (non-MS) — 60±14,7 y.o. Galectin-3 level was measured via immune-enzyme assay on “Platinum ELISA”.
Results. Mean level of galectin-3 in MS group was significantly higher and reached 1,89±1,71 ng/mL, comparing to non-MS group — 1,03±0,22 ng/mL (р=0,006). There were positive correlations of galectin-3 and CHD functional class by NYHA (r=0,346, р=0,012): in absence of CHD signs galectin-3 level was 1,05±0,26 ng/mL; in CHD of 1 functional class (FC) — 1,06±0,18 ng/mL; 2 FC — 1,7±1,59 ng/mL; 3 FC — 2,15±1,85 ng/mL.
Conclusion. The level of fibrosis marker galectin-3 are higher in MS patients than in non-MS, and in MS+CHD is higher than in those without this pathology. Finding of high level of galectin-3 in MS and CHD patients might witness on the severity of myocardial fibrosis, supporting prognosis.
About the Authors
O. М. Drapkina
National Research Center for Preventive Medicine
Russian Federation
Russian Federation
Moscow
R. N. Shepel
National Research Center for Preventive Medicine
Russian Federation
Russian Federation
Moscow
Т. A. Deeva
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Oganov RG, Mamedov MN. National clinical guidelines Russian Scientific Society of Cardiology. M: MEDI Expo 2009; р.392. Russian (Оганов Р. Г., Мамедов М. Н. Национальные клинические рекомендации Всероссийского научного общества кардиологов. М: МЕДИ Экспо, 2009; с.392).
2. Recommendations Project Experts of the Russian Society of Cardiology for the diagnosis and treatment of metabolic syndrome, the third revision of 2013. www.scardio.ru>content/Guidelines/projectrecomMS.doc (10 March 2016).
3. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
4. Maiolino G, Rossitto G, Pedon L, et al. Galectin-3 Predicts Long-Term Cardiovascular Death in High-Risk Patients With Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2015; 35: 725-32.
5. Lisowska A, Knapp M, Tycihska A, et al. Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study. Atherosclerosis 2016; 246: 309-17.
6. Weigert J, Neumeier M, Wanninger J, et al. Serum Galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 1404-11.
7. Yilmaz H, Cakmak M, Inan O, et al. Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? Journal of Endocrinological Investigation 2014; 38(5): 1-7.
8. Ionin VA, Listopad OV, Nifontov SE, et al. Galectin-3 in patients with metabolic syndrome and atrial fibrillation. Arterial Hypertension 2014; 5: 49-83. Russian (Ионин В. А., Листопад О. В., Нифонтов С. Е., и др. Галектин-3 у пациентов с метаболическим синдромом и фибрилляцией предсердий. Артериальная гипертензия 2014; 5: 49-83).
9. Alberti KGMM, Zimmet PZ, Shaw JE. The Metabolic Syndrome — A new worldwide definition from the International Diabetes Federation Consensus. Lancet 2005; 366: 1059-62.
Review
For citations:
Drapkina O.М., Shepel R.N., Deeva Т.A. GALECTIN-3 LEVEL IN pATIENTS WITH mETAbOLIC SYNDROmE AND CORONARY HEART DISEASE. Russian Journal of Cardiology. 2017;(3):30-36. (In Russ.) https://doi.org/10.15829/1560-4071-2017-3-30-36
Views:
1632
Email this article 